M. A. Bensmaïne

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

P. Chollet, E. Cvitkovic, H. Curé, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience.

S. Faivre, M. Marty, E. Cvitkovic, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

124 Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advance colorectal cancer (ACC)

F. Lévi, S. Brienza, C. Garufi, 1995 .

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

T. Petit, V. Diéras, P. Kerbrat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

M. Ducreux, F. Lévi, M. Marty, 2001, British Journal of Cancer.

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

M. Ducreux, P. Soulié, M. Marty, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

P. Soulié, E. Brain, J. Misset, 1999, Journal of Cancer Research and Clinical Oncology.